Table 6.
Clinical characteristics for the 22 reported liver transplant patients infected with COVID-19.
| Variable (n=22) | Value |
|---|---|
| Age (mean, range) | 55.96 (0.5–79) |
| Sex, Male | 15/22 (68.2%) |
| Liver transplant years age (mean, range) | 8.75 (0.005–26) |
| Within 1 year | 5/22 (22.7%) |
| Beyond 1 year | 17/22 (77.2%) |
| Comorbidities | |
| HTN | 4/22 (18.2%) |
| DM | 5/22 (22.7%) |
| Lung disease | 5/22 (22.7%) |
| Heart disease | 5/22 (22.7%) |
| Obesity | 1/22 (4.6%) |
| None or N/A | 9/22 (40.9%) |
| Clinical presentation | |
| Fever | 20/22 (90.9%) |
| Max. temp (average, SD) | 39.26 (±0.54) |
| Cough | 8/22 (36.7%) |
| SOB | 7/22 (31.8%) |
| Unspecified respiratory symptoms | 7/22 (31.8%) |
| Fatigue | 6/22 (27.3%) |
| Diarrhea | 7/22 (31.8%) |
| Laboratory | |
| White cell count | |
| Median (SD) per l | 3.2×109 (±1.56×109) |
| Leukopenia (<4×109/l) | 3/5 (60%) |
| Lymphocyte count | |
| Median (SD) per l | 0.67×109 (±0.18×109) |
| Lymphopenia (<1×109/l) | 6/6 (100%) |
| Initial C-reactive protein (CRP) | |
| Median (SD) | 21.5 (±15.6) |
| High CRP (>5 mg/dl) | 3/4 (75%) |
| Initial ALT | |
| Median (SD) | 80 (±101) |
| High ALT (>50 U/l) | 5/7 (71.4%) |
| Initial AST | |
| Median (SD) | 120 (±61.7) |
| High AST (>54 U/l) | 3/5 (60%) |